The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...

Chief Executive Officer Albert Bourla said at the JPMorgan Healthcare Conference on Monday. Bourla said the experts were helping Pfizer "make better and more sound decisions," and the company ...

Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

SAN FRANCISCO — At the end of a roundtable lunch with a group of reporters, Pfizer CEO Albert Bourla became impassioned. He admitted that after the company made a “big miscalculation” around ...

Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people familiar with the matter.

It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well ...

(NYSE:PFE) has temporarily avoided a standoff with activist investor Starboard Value LP. According to Bloomberg sources, ...

With morale at a low point, biotech and pharma CEOs are cautiously optimistic about the incoming Trump administration.

Swiss pharmaceutical giant Novartis (NVS) on Friday reported forecast-beating quarterly sales as its clutch of heart failure to breast cancer ...

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health ...